LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Merck & Co Inc.

Merck & Co Inc.

Suletud

Sektor Tervishoid

117.82 -0.52

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

117.67

Max

118.19

Põhinäitajad
By Trading Economics
Sissetulek	693M 5.5B
Müük	310M 16B
P/E Sektori keskmine	137.56 103.001
Aktsiakasum	2.28
Kasumimarginaal	33.861
Töötajad	72,000
EBITDA	491M 7.4B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+18.88 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024
Järgmine dividendimakse kuupäev	7. okt 2024
Järgmine aktsia dividendi kuupäev (ex-date)	16. sept 2024

Turustatistika
By TradingEconomics
Turukapital	1.8B 300B
Eelmine avamishind	118.34
Eelmine sulgemishind	117.82

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

116.6 / 118.395 Toetus ja vastupanu

Merck & Co Inc. Graafik

Seotud uudised

9. aug 2024, 11:14 UTC

Omandamised, ülevõtmised, äriostud

Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion

30. juuli 2024, 14:00 UTC

Tulu

Trending: Merck 2Q Profit Beats Expectations; Fiscal Year Adjusted EPS Outlook Lowered

30. juuli 2024, 11:17 UTC

Tulu

Merck Swings to 2Q Profit Ahead of Views, Lowers FY24 Adjusted EPS Outlook

3. sept 2024, 17:22 UTC

Peamised uudised

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

12. aug 2024, 14:30 UTC

Omandamised, ülevõtmised, äriostud

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12. aug 2024, 09:30 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Big Drugmakers Are Clinching Smaller Deals -- WSJ

1. aug 2024, 15:56 UTC

Tulu

Merck Created the World's Biggest Drug. Now It -2-

1. aug 2024, 15:56 UTC

Tulu

Merck Created the World's Biggest Drug. Now It Has to Replace It. -- Barrons.com

30. juuli 2024, 15:53 UTC

Tulu

Nasdaq Dives As Microsoft Earnings Loom; Two Dow Jones Leaders Crater On Earnings (Live Updates) -- IBD

30. juuli 2024, 15:28 UTC

Market Talk

Tulu

Merck's Keytruda Continues to See Growth in U.S., Abroad -- Market Talk

30. juuli 2024, 13:45 UTC

Tulu

Trending: Merck 2Q Profit Beats Expectations; FY Adj EPS Outlook Lowered

30. juuli 2024, 10:45 UTC

Tulu

Merck Beats Profit And Sales Expectations Amid Keytruda Strength, But Provides Mixed Full-Year Outlook -- MarketWatch

30. juuli 2024, 10:32 UTC

Tulu

Merck Revised 2024 Adjusted EPS View Includes 51c/Share Charge on EyeBio Deal >MRK

30. juuli 2024, 10:31 UTC

Tulu

Merck 2Q Sales Rose 11% Ex-Forex >MRK

30. juuli 2024, 10:31 UTC

Tulu

Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short -- IBD

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Keytruda Sales Up 16% >MRK

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Pharmaceutical Sales $14.41B >MRK

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Keytruda Sales $7.27B >MRK

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Gardasil/Gardasil 9 Sales Up 1% >MRK

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Januvia/Janumet Sales Down 27% >MRK

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Net $5.46B >MRK

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Januvia/Janumet Sales $629M >MRK

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Pharmaceutical Sales Up 7% >MRK

30. juuli 2024, 10:30 UTC

Tulu

Merck 2Q Gardasil/Gardasil 9 Sales $2.48B >MRK

30. juuli 2024, 08:38 UTC

Peamised uudised

These Stocks Are Moving the Most Today: Microsoft, CrowdStrike, F5, Lattice Semiconductor, BP, Tilray, and More -- Barrons.com

28. juuli 2024, 23:02 UTC

Peamised uudised

Stocks Poised for Higher Open -- Barrons.com

12. juuli 2024, 10:45 UTC

Omandamised, ülevõtmised, äriostud

Merck to Post 3Q Charge of About $1.3 Billion, or 50c/Share, on EyeBio Deal >MRK

12. juuli 2024, 10:45 UTC

Omandamised, ülevõtmised, äriostud

Merck Completes Acquisition Of EyeBio >MRK

9. juuli 2024, 12:30 UTC

Omandamised, ülevõtmised, äriostud

Merck Animal Health Completes Acquisition Of Elanco's Aqua Business >MRK

9. juuli 2024, 12:29 UTC

Omandamised, ülevõtmised, äriostud

Elanco Animal Health Sees Ending 2024 With Net Debt to Adjusted Ebitda in Mid-4x Range >ELAN

Võrdlus sarnastega

Hinnamuutus

Merck & Co Inc. Prognoos

Hinnasiht

By TipRanks

18.88% tõus

12 kuu keskmine prognoos

Keskmine 140.09 USD 18.88%

Kõrge 155 USD

Madal 125 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Merck & Co Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

Osta

Hoia

Müü

Põhineb 16 analüütiku instrumendi Merck & Co Inc. aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

116.6 / 118.395Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Merck & Co Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.